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Background: Use of inappropriate drugs is common among institutionalized older people. Rigorous trials
investigating the effect of the education of staff in institutionalized settings on the harm related to older people’s
drug treatment are still scarce. The aim of this trial is to investigate whether training professionals in assisted living
facilities reduces the use of inappropriate drugs among residents and has an effect on residents’ quality of life and
use of health services.
Methods and design: During years 2011 and 2012, a sample of residents in assisted living facilities in Helsinki
(approximately 212) will be recruited, having offered to participate in a trial aiming to reduce their harmful drugs.
Their wards will be randomized into two arms: one, those in which staff will be trained in two half-day sessions,
including case studies to identify inappropriate, anticholinergic and psychotropic drugs among their residents, and
two, a control group with usual care procedures and delayed training. The intervention wards will have an
appointed nurse who will be responsible for taking care of the medication of the residents on her ward, and taking
any problems to the consulting doctor, who will be responsible for the overall care of the patient. The trial will last
for twelve months, the assessment time points will be zero, six and twelve months.
The primary outcomes will be the proportion of persons using inappropriate, anticholinergic, or more than two
psychotropic drugs, and the change in the mean number of inappropriate, anticholinergic and psychotropic drugs
among residents. Secondary endpoints will be, for example, the change in the mean number of drugs, the
proportion of residents having significant drug-drug interactions, residents' health-related quality of life (HRQOL)
according to the 15D instrument, cognition according to verbal fluency and clock-drawing tests and the use and
cost of health services, especially hospitalizations.
Discussion: To our knowledge, this is the first large-scale randomized trial exploring whether relatively light
intervention, that is, staff training, will have an effect on reducing harmful drugs and improving QOL among
institutionalized older people.
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Polypharmacy and use of inappropriate drugs is very
common among frail institutionalized residents [1-3].
Older people living in nursing homes and institutions
are administered an average eight to ten medications
[2,4]. Polypharmacy is a challenge for clinicians, because
it is associated with a risk of drug-drug interactions and
adverse effects [5]. In institutional settings, polyphar-
macy has been defined as using more than eight drugs
[6], or ten or more drugs [7].
Inappropriate medications for older people have been
defined in several different ways [8-11]. The criteria may
be explicit, that is, drug- or disease-oriented, implemen-
ted to all patients in a similar way, and thus, simple to
use [12]. The criteria may be also implicit, that is, based
on clinical judgment; they may include more compli-
cated domains such as effectiveness, drug-drug interac-
tions, lowest cost or duplications. These kinds of criteria
are more comprehensive, but also more complicated to
use [12]. The most widely used international explicit cri-
teria have been developed by Beers’ expert panel [8,9].
Of Finnish elderly residents in institutional care, 36%
were on the Beers’ list of inappropriate drugs [1,13]. This
proportion is similar or lower than those found in re-
spective American or Australian studies [14,15]. Use of
inappropriate medications may not increase mortality,
but it may result in unnecessary hospitalizations [16].
The Omnibus Budget Reconciliation Act of 1987 in the
USA succeeded in decreasing the use of harmful psychi-
atric medications among older people [17]. There have
been warnings concerning the use of antipsychotics in
patients with dementia, with an increased risk of stroke
and mortality [18,19]. The use of psychotropic drugs is
associated with risk of falls [20]. There is extensive use of
psychotropic drugs in Finnish nursing homes, 80% being
administered at least one psychotropic drug [4].
There is also increasing evidence of the adverse effects
of drugs with anticholinergic properties. In addition to the
traditional side effects such as dryness of mouth, constipa-
tion and worsening glaucoma, they have been shown to be
associated with cognitive decline [21,22], and they may in-
crease the risk of hospital admissions [23]. They may be
particularly harmful for older people with cognitive de-
cline and dementia, such as for those in institutional care.
In recent studies, particular attention has been paid to the
use of anticholinergic drugs and defining them [22,24].
The criteria of the Swedish National Board of Health
and Welfare (Socialstyrelsen) for inappropriate drugs for
older people include also the long-term use of nonsteroi-
dal anti-inflammatory drugs (NSAID) and tramadol [7].
There is also increasing evidence that long-term use of
proton pump inhibitors (PPI) among frail elderly institu-
tionalized residents is associated with infections, hip
fractures and even higher mortality [25].Drug-drug interactions are of concern and they are
associated with adverse events [26]. Swedish Finnish
INteraction X-referencing (SFINX) is a commercial medical
interaction database that includes information on >6200
drug-drug interactions and it is updated quarterly by spe-
cialists in clinical pharmacology [27]. The potential drug-
drug interactions in the SFINX database are classified
according to their clinical significance and level of docu-
mentation. Clinical significance is classified from A to D,
where A means the interaction is clinically insignificant and
D means the interaction is clinically significant and the
combination should be avoided [26].
At least 20 randomized controlled studies have been
performed aiming to reduce the use of potentially in-
appropriate drugs among older people living in nursing
homes. However, most studies have been of low quality,
and thus, have risk of bias [28]. According to a recent
systematic review, interventions using educational out-
reach, on-site education and pharmacist medication
reviews may reduce inappropriate drug use [28]. Suc-
cessful educational interventions have been performed
to decrease the use of psychotropic medications for
institutionalized elderly patients [29-33] and to improve
the quality of drug prescribing [34,35]. However, only a
few studies have explored the intervention effects on
older people’s well-being or their use of health services.
The aim of this study is to determine whether training
nurses in assisted living facilities in Helsinki would re-
duce the use of inappropriate medications, anticholiner-
gic and psychotropic drugs among the residents in these
houses. In addition, we will examine the effect of inter-
vention on quality of life (QOL), cognition, and use and
costs of health services of the participating older people.
Methods
General design
The study is a randomized controlled trial in which wards
in assisted living facilities in Helsinki are randomly allocated
to two arms. The staff in intervention wards will receive
two half-day training sessions concerning appropriate use
of drugs among frail older people. Approximately 212
patients will be included: 100 subjects in the intervention
group and 100 in the control group. The number of
patients per group may vary, because the wards randomized
may vary in size. The study has been approved by the ethics
committee of Helsinki University Central Hospital. Informed
consent has been obtained from each patient and/or their
closest proxy before any study procedure is performed
according to good clinical practice.
Participants
Older residents residing in assisted living facilities in
Helsinki will be recruited one by one by approaching
them and their closest proxy.
Figure 1 Flow chart.
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assisted living facilities:
– 65 years or older, living permanently in assisted
living facilities in Helsinki
– a native speaker of the Finnish language
– uses at least one drug
– no terminal illness (estimated prognosis
>6 months), and
– voluntary participation, written informed consent to
participate in the study given by participant or her/
his closest proxy.
Those residents fulfilling the inclusion criteria are
invited for the first study nurse visit. In case of the parti-
cipants’ cognitive decline (Mini Mental State Examin-
ation (MMSE) <20) [36] or poor judgment capability,
the proxy is invited to give consent in addition to the
participant.
Study procedures
The baseline study visit lasts about one hour and includes
an interview to ascertain residents’ demographic data,
diagnoses, and medications used. The diagnoses and med-
ications are confirmed from medical records.
The participant will be assessed using the clinical de-
mentia rating scale (CDR) [37], Mini Mental State
Examination (MMSE) [36], verbal fluency [38,39], the
clock-drawing test [40], and Mini Nutritional Assess-
ment (MNA) [41]. Patients’ psychological well-being will
be assessed using the psychological well-being (PWB)
scale [42] and health-related quality of life (HRQOL) will
be assessed by 15D measure [43]. Participants will be
assessed by two study nurses three times during the
year: at baseline, and at six and twelve months. The flow
chart of the study is presented in Figure 1, and study as-
sessment procedures are described in Table 1. Hospitali-
zations, use of other health and social services and death
dates will be retrieved from the central registers for one
year from baseline measurements.
Drug use will be assessed as the point prevalence on
the day of assessment. Residents will be classified as
regular drug users if their medical charts indicate a regu-
lar sequence of administration on a daily basis. Add-
itional analyses will be performed including both
regularly used drugs as well as drugs used on a pro re
nata (prn, or as needed) basis. The drugs administered
to residents will be classified according to the anatom-
ical therapeutic chemical (ATC) classification system
recommended by the World Health Organization
(WHO) [44]. The drugs that will be considered as in-
appropriate, having anticholinergic properties or being
psychotropic drugs are presented in Additional file 1:
Table S1. The total number of these drugs each residentis using one, on a regular daily basis and two, both regu-
larly or prn will be counted.
We randomized wards instead of individual partici-
pants in order to avoid contamination. The wards
selected for this study were all using the Minimum Data
Set (MDS)/Resident Assessment Instrument (RAI) ver-
sion 2.0 for home care [45]. MDS is used for assessing
the residents’ needs and for individual care planning
purposes. Each nurse has been educated to use MDS,
and the assessment is routinely performed twice annu-
ally or whenever there is a substantial change in the resi-
dent’s status. In addition to the internationally well-
validated scales and items, MDS provides a patient’s
ward profile, often called ‘the case-mix’ (for example,
‘psychogeriatric’, ‘physically disabled’ or ‘cognitively
impaired’), and gives the mean level of residents’ need
for assistance. After identifying the case-mix in each of
the wards, the wards will be divided into dyads having
approximately the same characteristics. These dyads will
be further randomized, by means of computer-generated
random numbers, into two arms: those to receive staff
training or to receive education after the trial. In
addition, individual RAI items (for example, the propor-
tion of fallers) and some of the well-validated RAI scale
items (for example, neuropsychiatric symptoms, symp-
toms of delirium) will be used in measuring the effects
of intervention.
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CDR, clinical dementia rating scale (Hughes et al. 1982); MMSE, Mini Mental
State Examination (Folstein et al. 1972); MNA,Mini Nutritional Assessment
(Guigoz et al. 2002); 15D, health-related quality of life scale (Sintonen et al.
1990); PWB, psychological well-being scale (Routasalo et al. 2009);
RAI, Resident Assessment Instrument (Morris et al. 2000).
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In intervention wards, the nurses and consultant physician,
if available, will receive training with emphasis on drug
safety, inappropriate drugs for older people, drugs with
anticholinergic properties, problems related to psychotropic
drugs and the adverse effects related to NSAIDs and PPIs.
D-class interactions of drugs will be discussed. We will also
give information in these educational sessions about
evidence-based treatments in this patient group. The train-
ing will be organized as an activating discussion session
separately for each intervention ward. Cases related to their
own residents will be discussed. Two educational sessions
per ward will be organized. In addition, nurses responsible
for pharmaceuticals will be provided with more intensive
training, together with others responsible for drugs,
regarding procedures and processes of how to reduce drug
use. A list of inappropriate drugs will be provided to all
nurses working in intervention wards. In addition, for
each intervention ward a nurse responsible for drugs will
be appointed. She/he will bring potential drug problems
to the consulting physician in assisted living. In institu-
tions, assisted living facilities and nursing homes in
Helsinki, physicians act as visiting consultants to whomthe nurses take problematic cases. The physician will take
the final responsibility to change or to continue the drugs.
The control wards will continue with the usual care
processes. The staff in these wards will receive training
in drug treatment after the study is over.
Outcome measurements
The research nurses perform their assessments at zero,
six and twelve months.
Primary outcome measures are:
 the proportion of persons using inappropriate,
anticholinergic or more than two psychotropic
drugs (these drugs are presented in Additional file 1:
Table S1), and
 the change in the mean number of inappropriate,
anticholinergic and psychotropic drugs.
Secondary outcome measures are:
 change in the mean WHO-defined daily dose [44] of
inappropriate, anticholinergic or psychotropic drugs
 the proportion of persons with significant drug-drug
interactions according to SFINX [27]
 the number of drug-related problems [46]
 change in the mean number of drugs
 change in the proportion of participants having nine
or more drugs
 use of health care services and their costs during a
12-month follow-up
 the number of hospitalizations/follow-up time
 the 15D HRQOL measure [43]
 cognition according to verbal fluency and clock-
drawing test [38-40], and CDR sum of boxes [37]
 change in neuropsychiatric symptoms or symptoms
of delirium according to the RAI instrument [45],
and
 the number of fallers according to the RAI
instrument [45].
Statistical analyses
Required sample size calculation is based upon the
change in the proportion of users of inappropriate, anti-
cholinergic or psychotropic drugs. Sample size was cal-
culated as follows: if in the control group 36% use
inappropriate drugs, the minimum group difference with
the assessment is 20%, type I error 5%, power 80%,
which results in 106/group. Because we recruit partici-
pants from wards and aim to include as many as pos-
sible from those wards, the final sample size may differ
slightly from this figure.
In these baseline findings, for the continuous variables,
descriptive values will be expressed by means with
standard deviations (SD) and medians with range. For
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istical comparisons between the groups will be made by
using a t test. If the variables have a non-normal distri-
bution or ordinal level, statistical comparison between
groups will be performed with the Mann Whitney U
test. Measures with a discrete distribution will be expressed
as percentages (%) and analyzed by X2 or Fischer’s exact test
when appropriate.
The results will be analyzed according to intention to
treat. For imputation method, ‘the last observation car-
ried forward’ (LOCF) and ‘worst-rank score’ principle
will be used. For the most important outcome para-
meters, estimation of confidence interval (95%) will be
used in addition to testing. Since the distributions of
health care costs are highly skewed, the differences be-
tween means and confidence intervals are estimated
using the bootstrap method (bias corrected and acceler-
ated bootstrapping).
Discussion
This rigorous randomized trial will test whether a rela-
tively light educational intervention will have an effect
on the use of inappropriate, anticholinergic and psycho-
tropic drugs use among frail older residents in assisted
living facilities. The drugs considered in this trial include
a wide variety of potentially harmful drugs that have
been shown in recent years to have adverse effects in
this particular patient group. Intervention is pragmatic
in nature, and its potential effects rely on those profes-
sionals who actually work with these older people. The
nurses will be trained to identify the harmful drugs,
whereas the final decision to stop these medications will
be made by physicians consulting to these wards. Thus,
if the intervention proves to be effective, it can be imple-
mented easily.
The strength of this study is its pragmatic nature and
easily implemented training. Thus, the findings should
be applicable in real life. The population is frail and vul-
nerable and, according to our previous studies, uses a
high number of these drugs. Thus, the floor effect is not
easily reached in the primary endpoint. Besides the num-
ber of potentially harmful drugs, this study will also
examine the effects of intervention on residents’ QOL.
Contrary to many previous trials, this study will also col-
lect data on participants’ hospitalizations. Inappropriate
drugs according to Beers, anticholinergic drugs, as well
as psychotropic drugs have been suggested to increase
hospitalizations and complications [16,19,23,25].
However, there are also potential limitations in this
study. First, the population is old and frail with many
comorbidities, and, thus, vulnerable to competing causes
of complications and deaths. This may decrease the
power of the study. The second challenge relates to a
sufficient difference to be attained between the groupswith our intervention. Contamination might be a prob-
lem, because the staff changes rapidly in these institu-
tions and they may also move from intervention site to
control site. The staff is also stressed, and it is unclear
how they will accept our training. In addition, the staff
will also learn about evidence-based treatments in this
patient group (such as the beneficial effects of vitamin
D, stroke prevention, dementia drugs, pain treatment),
which may increase the number of medications, and,
thus, may even have effects in the opposite direction
from that intended in this study.
To our knowledge, this is the first large-scale interven-
tion trial exploring the effects of educational interven-
tion on reducing a wide variety of harmful drugs in
institutionalized older people, as well as on their QOL,
cognition and hospitalizations. This study will provide
data whether modern learning methods have effects on
decreasing the harmful consequences of these drugs.
Trial status
Ongoing, patient recruitment not completed at the time
of submission.
Additional file
Additional file 1: Table S1. Drugs considered as inappropriate,
psychotropic or anticholinergic drugs in the present study.
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